Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine for ALS (TAME Study)
NCT02118727Phase 2Completed
- Sponsor
- University of Kansas Medical Center
- Start
- Nov 2018
- Primary completion
- Jul 2021
- Countries
- 1
01
Overview
A Phase 2 trial of memantine in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), sponsored by University of Kansas Medical Center. Started Nov 2018; status: completed.
02
Drugs
memantine
03
Conditions
amyotrophic lateral sclerosis (ALS)frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NCT02118727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02118727.